| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL NATURE 415 (6869): 335-339 JAN 17 2002 and the citing papers |
Nodes: 165
Authors: 807,
Journals: 63,
Outer References: 4973
Collection span: 2002 - 2004
View: Overview. Sorted by date.
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
|---|---|---|---|---|---|
| 1 | 1 | 15 | 36 2002 JAN 17 NATURE 415(6869):272-273
Lifson JD; Martin MA AIDS vaccines - One step forwards, one step back | 9 | 12 |
| 2 | 0 | 27 | 37 2002 JAN 17 NATURE 415(6869):335-339
Barouch DH; Kunstman J; Kuroda MJ; Schmitz JE; Santra S; Peyerl FW; Krivulka GR; Beaudry K; Lifton MA; Gorgone DA; Montefiori DC; Lewis MG; Wolinsky SM; Letvin NL Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes | 164 | 164 |
| 3 | 2 | 4 | 33 2002 JAN 19 LANCET 359(9302):235-235
Senior K HIV-vaccine research takes one steps forward ... and one step back | 0 | 1 |
| 4 | 1 | 3 | 40 2002 FEB [15] NATURE REVIEWS IMMUNOLOGY 2(2):69-69
Bell E Keep right on to the end of the road... | 0 | 0 |
| 5 | 1 | 35 | 39 2002 MAR [15] NATURE MEDICINE 8(3):207-210
Feinberg MB; Moore JP AIDS vaccine models: Challenging challenge viruses | 7 | 26 |
| 6 | 2 | 116 | 41 2002 APR [15] NATURE REVIEWS IMMUNOLOGY 2(4):239-250
Robinson HL New hope for an AIDS vaccine | 11 | 35 |
| 7 | 1 | 126 | 42 2002 APR [15] NATURE REVIEWS IMMUNOLOGY 2(4):283-291
McMichael A; Hanke T The quest for an AIDS vaccine: is the CD8(+) T-cell approach feasible? | 8 | 30 |
| 8 | 2 | 16 | 44 2002 MAY 24 SCIENCE 296(5572):1410-1411
McMichael A; Klenerman P HIV/AIDS - HLA leaves its footprints on HIV | 1 | 5 |
| 9 | 1 | 30 | 45 2002 MAY 24 SCIENCE 296(5572):1439-1443
Moore CB; John M; James IR; Christiansen FT; Witt CS; Mallal SA Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level | 22 | 84 |
| 10 | 1 | 31 | 19 2002 JUN [15] IMMUNOLOGY AND CELL BIOLOGY 80(3):300-306
Schonbach C; Kun Y; Brusic V Large-scale computational identification of HIV T-cell epitopes | 0 | 2 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 11 | 1 | 23 | 27 2002 JUN [15] JOURNAL OF VIROLOGY 76(12):6376-6381
Santra S; Barouch DH; Kuroda MJ; Schmitz JE; Krivulka GR; Beaudry K; Lord CI; Lifton MA; Wyatt LS; Moss B; Hirsch VM; Letvin NL Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection | 2 | 5 |
| 12 | 1 | 166 | 34 2002 JUN [15] LANCET INFECTIOUS DISEASES 2(6):353-367
Vandepapeliere P Therapeutic vaccination against chronic viral infections | 0 | 4 |
| 13 | 3 | 115 | 1 2002 [JUN 30] AIDS 16():S3-S16
Najera R; Delgado E; Perez-Alvarez L; Thomson MM Genetic recombination and its role in the development of the HIV-1 pandemic | 0 | 5 |
| 14 | 2 | 103 | 2 2002 [JUN 30] AIDS 16():S115-S124
O'Hagan DT; Lavelle E Novel adjuvants and delivery systems for HIV vaccines | 0 | 2 |
| 15 | 2 | 102 | 3 2002 [JUN 30] AIDS 16():S125-S132
Lehner T; Anton PA Mucosal immunity and vaccination against HIV | 0 | 1 |
| 16 | 1 | 41 | 5 2002 [JUN 30] BRITISH MEDICAL BULLETIN 62():87-98
McMichael A; Mwau M; Hanke T Design and tests of an HIV vaccine | 1 | 4 |
| 17 | 2 | 12 | 20 2002 JUL-DEC [JUL 15] INTERVIROLOGY 45(4-6):260-266
Marcus U; Dittmar MT; Krausslich HG HIV: Epidemiology and strategies for therapy and vaccination | 0 | 0 |
| 18 | 1 | 27 | 21 2002 JUL [15] JOURNAL OF CLINICAL INVESTIGATION 110(1):15-20
Letvin NL Strategies for an HIV vaccine | 6 | 18 |
| 19 | 2 | 11 | 6 2002 JUL 26 CELL 110(2):135-138
Ho DD; Huang YX The HIV-1 vaccine race | 3 | 15 |
| 20 | 2 | 69 | 9 2002 AUG [15] CURRENT OPINION IN IMMUNOLOGY 14(4):487-494
Gandhi RT; Walker BD Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection | 1 | 4 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 21 | 1 | 67 | 10 2002 AUG [15] CURRENT OPINION IN IMMUNOLOGY 14(4):495-502
Ferrantelli F; Ruprecht RM Neutralizing antibodies against HIV - back in the major leagues? | 8 | 23 |
| 22 | 2 | 49 | 11 2002 AUG [15] CURRENT OPINION IN MICROBIOLOGY 5(4):408-413
Klenerman P; Wu Y; Phillips R HIV: current opinion in escapology | 7 | 20 |
| 23 | 1 | 39 | 25 2002 AUG [15] JOURNAL OF MEDICAL PRIMATOLOGY 31(4-5):179-185
Muthumani K; Bagarazzi M; Conway D; Hwang DS; Ayyavoo V; Zhang D; Manson K; Kim J; Boyer J; Weiner DB Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques | 1 | 1 |
| 24 | 1 | 85 | 26 2002 AUG [15] JOURNAL OF MEDICAL PRIMATOLOGY 31(4-5):237-256
Warren J Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates | 2 | 4 |
| 25 | 1 | 39 | 28 2002 AUG [15] JOURNAL OF VIROLOGY 76(15):7444-7452
Ramos A; Hu DJ; Nguyen L; Phan KO; Vanichseni S; Promadej N; Choopanya K; Callahan M; Young NL; McNicholl J; Mastro TD; Folks TM; Subbarao S Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users | 3 | 27 |
| 26 | 1 | 13 | 46 2002 AUG 23 SCIENCE 297(5585):1276-1277
Lehner T; Shearer GM Alternative HIV vaccine strategies | 0 | 1 |
| 27 | 2 | 162 | 8 2002 SEP [15] CLINICS IN LABORATORY MEDICINE 22(3):773-+
Piazza P; Fan Z; Rinaldo CR CD8+T-cell immunity to HIV infection | 0 | 0 |
| 28 | 1 | 6 | 12 2002 SEP [15] DNA AND CELL BIOLOGY 21(9):597-598
Robert-Guroff M HIV regulatory and accessory proteins: New targets for vaccine development | 0 | 0 |
| 29 | 2 | 42 | 13 2002 SEP [15] DNA AND CELL BIOLOGY 21(9):611-618
Gallo RC; Burny A; Zagury D Targeting Tat and IFN alpha as a therapeutic AIDS vaccine | 1 | 2 |
| 30 | 1 | 55 | 14 2002 SEP [15] DNA AND CELL BIOLOGY 21(9):619-626
Hel Z; Tryniszewska E; Tsai WP; Johnson JM; Harrod R; Fullen J; Kalyanaraman VS; Altman JD; McNally J; Karpova T; Felber BK; Tartaglia J; Franchini G Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes | 1 | 1 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 31 | 1 | 47 | 15 2002 SEP [15] DNA AND CELL BIOLOGY 21(9):637-651
Richardson MW; Mirchandani J; Silvera P; Regulier EG; Capini C; Bojczuk PM; Hu J; Graceley EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J Immunogenicity of HIV-1IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: Induction of humoral and cellular immune responses | 3 | 4 |
| 32 | 1 | 27 | 16 2002 SEP [15] DNA AND CELL BIOLOGY 21(9):659-664
O'Connor DH; Allen TM; Watkins DI Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies | 0 | 5 |
| 33 | 2 | 41 | 17 2002 SEP [15] DNA AND CELL BIOLOGY 21(9):671-678
Addo MM; Yu XG; Rosenberg ES; Walker BD; Altfeld M Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection | 1 | 2 |
| 34 | 1 | 35 | 18 2002 SEP [15] DNA AND CELL BIOLOGY 21(9):689-695
Muthumani K; Hwang DS; Dayes NS; Kim JJ; Weiner DB The HIV-1 accessory gene vpr can inhibit antigen-specific immune function | 1 | 2 |
| 35 | 1 | 48 | 29 2002 SEP [15] JOURNAL OF VIROLOGY 76(17):8690-8701
Yu XG; Addo MM; Rosenberg ES; Rodriguez WR; Lee PK; Fitzpatrick CA; Johnston MN; Strick D; Goulder PJR; Walker BD; Altfeld M Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8(+) T-cell responses following acute HIV-1 infection | 10 | 21 |
| 36 | 1 | 63 | 51 2002 SEP [15] TRENDS IN IMMUNOLOGY 23(9):456-460
Allen TM; Kelleher AD; Zaunders J; Walker BD STI and beyond: the prospects of boosting anti-HIV immune responses | 1 | 7 |
| 37 | 1 | 8 | 49 2002 SEP 16 SCIENTIST 16(18):28-29
Russo E Scientists combine two approaches to thwart the spread of HIV | 0 | 0 |
| 38 | 1 | 32 | 23 2002 OCT 1 JOURNAL OF IMMUNOLOGY 169(7):3694-3699
Boissonnas A; Bonduelle O; Antzack A; Lone YC; Gache C; Debre P; Autran B; Combadiere B In vivo priming of HIV-specific CTLs determines selective cross-reactive immune responses against poorly immunogenic HIV-natural variants | 0 | 0 |
| 39 | 2 | 28 | 43 2002 OCT 7 PROCEEDINGS OF THE ROYAL SOCIETY OF LONDON SERIES B-BIOLOGICAL SCIENCES 269(1504):2035-2040
Kamp C; Bornholdt S From HIV infection to AIDS: a dynamically induced percolation transition? | 0 | 1 |
| 40 | 1 | 63 | 4 2002 OCT-NOV [OCT 15] BIOFUTUR (226):52-58
Allen TM; Kelleher AD; Zaunders J; Walker BD Structured treatment interruption and beyond | 0 | 0 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 41 | 1 | 25 | 30 2002 OCT [15] JOURNAL OF VIROLOGY 76(19):10038-10043
Caulfield MJ; Wang S; Smith JG; Tobery TW; Liu X; Davies ME; Casimiro DR; Fu TM; Simon A; Evans RK; Emini EA; Shiver J Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus Gag DNA Vaccines | 1 | 9 |
| 42 | 2 | 27 | 31 2002 OCT [15] JOURNAL OF VIROLOGY 76(20):10147-10154
Tang YY; Villinger F; Staprans SI; Amara RR; Smith JM; Herndon JG; Robinson HL Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges | 2 | 3 |
| 43 | 1 | 101 | 32 2002 OCT [15] JOURNAL OF VIROLOGY 76(20):10155-10168
Novitsky V; Cao H; Rybak N; Gilbert P; McLane MF; Gaolekwe S; Peter T; Thior I; Ndung'u T; Marlink R; Lee TH; Essex M Magnitude and frequency of cytotoxic T-lymphocyte responses: Identification of immunodominant regions of human immunodeficiency virus type 1 subtype C | 5 | 12 |
| 44 | 2 | 51 | 52 2002 OCT [15] TRENDS IN MOLECULAR MEDICINE 8(10):489-495
Amara RR; Robinson HL A new generation of HIV vaccines | 2 | 4 |
| 45 | 1 | 46 | 47 2002 NOV 1 SCIENCE 298(5595):995-1000
Zhang LQ; Yu WJ; He T; Yu J; Caffrey RE; Dalmasso EA; Fu SY; Pham T; Mei JF; Ho JJ; Zhang WY; Lopez P; Ho DD Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor | 5 | 97 |
| 46 | 2 | 99 | 7 2002 NOV [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(2):172-182
Shacklett BL Beyond Cr-51 release: new methods for assessing HIV-1-specific CD8(+) T cell responses in peripheral blood and mucosal tissues | 0 | 3 |
| 47 | 1 | 114 | 22 2002 NOV [15] JOURNAL OF HEPATOLOGY 37(5):684-695
Forns X; Bukh J; Purcell RH The challenge of developing a vaccine against hepatitis C virus | 0 | 4 |
| 48 | 1 | 45 | 35 2002 NOV [15] MICROBES AND INFECTION 4(13):1301-1307
Crotty S; Andino R Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin | 0 | 1 |
| 49 | 2 | 24 | 38 2002 NOV [15] NATURE IMMUNOLOGY 3(11):987-989
Phillips RE Immunology taught by Darwin | 1 | 4 |
| 50 | 1 | 67 | 50 2002 NOV [15] TRENDS IN BIOTECHNOLOGY 20(11):479-484
Wolfgang MJ; Golos TG Nonhuman primate transgenesis: progress and prospects | 0 | 0 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 51 | 1 | 9 | 48 2002 NOV 29 SCIENCE 298(5599):1730-1731
Gallo RC; Montagnier L Historical essay - Enhanced Prospects for the future | 0 | 7 |
| 52 | 1 | 49 | 55 2002 DEC 5 VIROLOGY 304(1):125-134
Hel Z; Nacsa J; Tsai WP; Thornton A; Giuliani L; Tartaglia J; Franchini G Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SlVmac251-infected macaques | 0 | 3 |
| 53 | 1 | 19 | 24 2002 DEC 15 JOURNAL OF IMMUNOLOGY 169(12):6779-6786
Singh RAK; Rodgers JR; Barry MA The role of T cell antagonism and original antigenic sin in genetic immunization | 0 | 2 |
| 54 | 2 | 36 | 53 2002 DEC 19 VACCINE 20():A61-A65
Ferrantelli F; Rasmussen RA; Hofmann-Lehmann R; Xu WD; McClure HM; Ruprecht RM Do not underestimate the power of antibodies - lessons from adoptive transfer of antibodies against HIV | 0 | 0 |
| 55 | 1 | 15 | 54 2002 DEC 19 VACCINE 20():A66-A68
Barouch DH; Letvin NL Viral evolution and challenges in the development of HIV vaccines | 0 | 4 |
| 56 | 1 | 46 | 126 2003 JAN 5 VIROLOGY 305(1):210-218
Nacsa J; Stanton J; Kunstman KJ; Tsai WP; Watkins DI; Wolinsky SM; Franchini G Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251 | 2 | 2 |
| 57 | 7 | 23 | 62 2003 JAN [15] BIOMEDICINE & PHARMACOTHERAPY 57(1):1-3
Rappaport J Perspectives in HIV pathogenesis, treatment, and prevention | 0 | 1 |
| 58 | 2 | 71 | 63 2003 JAN [15] BIOMEDICINE & PHARMACOTHERAPY 57(1):4-14
Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection | 1 | 3 |
| 59 | 7 | 177 | 67 2003 JAN [15] CURRENT HIV RESEARCH 1(1):101-120
Spearman P HIV vaccine development: Lessons from the past and promise for the future | 1 | 4 |
| 60 | 1 | 131 | 71 2003 JAN [15] FRONTIERS IN BIOSCIENCE 8():D143-D155
Hu WS; Rhodes T; Dang Q; Pathak V Retroviral recombination: Review of genetic analyses | 0 | 0 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 61 | 1 | 30 | 78 2003 JAN [15] JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 51(1):1-4
Lange CG; Lederman MM Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection | 1 | 4 |
| 62 | 1 | 117 | 80 2003 JAN [15] JOURNAL OF GENE MEDICINE 5(1):3-10
Mwau M; McMichael AJ A review of vaccines for HIV prevention | 0 | 4 |
| 63 | 2 | 82 | 88 2003 JAN [15] JOURNAL OF VIROLOGY 77(2):1049-1058
Voss G; Manson K; Montefiori D; Watkins DI; Heeney J; Wyand M; Cohen J; Bruck C Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine | 1 | 3 |
| 64 | 1 | 83 | 89 2003 JAN [15] JOURNAL OF VIROLOGY 77(2):1163-1174
Willey RL; Byrum R; Piatak M; Kim YB; Cho MW; Rossio JL; Bess J; Igarashi T; Endo Y; Arthur LO; Lifson JD; Martin MA Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles | 3 | 12 |
| 65 | 3 | 12 | 111 2003 JAN [15] NATURE IMMUNOLOGY 4(1):12-13
Robinson HL T cells versus HIV-1: fighting exhaustion as well as escape | 0 | 0 |
| 66 | 2 | 16 | 112 2003 JAN [15] NATURE MEDICINE 9(1):13-14
Bhardwaj N; Walker BD Immunotherapy for AIDS virus infections: Cautious optimism for cell-based vaccine | 1 | 4 |
| 67 | 1 | 37 | 113 2003 JAN [15] NATURE MEDICINE 9(1):27-32
Lu W; Wu XX; Lu YZ; Guo WZ; Andrieu JM Therapeutic dendritic-cell vaccine for simian AIDS | 4 | 19 |
| 68 | 2 | 25 | 121 2003 JAN 30 VACCINE 21(7-8):629-637
Muthumani K; Bagarazzi M; Conway D; Hwang DS; Manson K; Ciccarelli R; Israel Z; Montefiori DC; Ugen K; Miller N; Kim J; Boyer J; Weiner DB A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in Rhesus Macaques | 1 | 2 |
| 69 | 1 | 36 | 127 2003 FEB 1 VIROLOGY 306(1):116-125
Cheevers WP; Snekvik KR; Trujillo JD; Kumpula-McWhirter NMK; Top KJPO; Knowles DP Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis | 0 | 0 |
| 70 | 1 | 15 | 59 2003 FEB [15] AIDS PATIENT CARE AND STDS 17(2):47-51
Johnston R AIDSVAX results: An answer, or just more questions? | 1 | 1 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 71 | 5 | 111 | 69 2003 FEB [15] CURRENT OPINION IN MOLECULAR THERAPEUTICS 5(1):25-32
Hanke T Development of prophylactic AIDS vaccines: The current state of affairs | 1 | 2 |
| 72 | 1 | 48 | 72 2003 FEB [15] IMMUNITY 18(2):289-299
Bobbitt KR; Addo MM; Altfeld M; Filzen T; Onafuwa AA; Walker BD; Collins KL Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing | 0 | 4 |
| 73 | 1 | 68 | 90 2003 FEB [15] JOURNAL OF VIROLOGY 77(3):2046-2055
Green TD; Montefiori DC; Ross TM Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d | 2 | 8 |
| 74 | 2 | 51 | 91 2003 FEB [15] JOURNAL OF VIROLOGY 77(3):2081-2092
Addo MM; Yu XG; Rathod A; Cohen D; Eldridge RL; Strick D; Johnston MN; Corcoran C; Wurcel AG; Fitzpatrick CA; Feeney ME; Rodriguez WR; Basgoz N; Draenert R; Stone DR; Brander C; Goulder PJR; Rosenberg ES; Altfeld M; Walker BD Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load | 9 | 36 |
| 75 | 1 | 40 | 117 2003 FEB [15] TRENDS IN IMMUNOLOGY 24(2):67-72
Yang OO Will we be able to 'spot' an effective HIV-1 vaccine? | 2 | 7 |
| 76 | 1 | 42 | 115 2003 MAR 18 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 100(6):3392-3397
Oh S; Berzofsky JA; Burke DS; Waldmann TA; Perera LP Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity | 0 | 8 |
| 77 | 1 | 47 | 128 2003 MAR 30 VIROLOGY 308(1):178-190
Ambrose Z; Thompson J; Larsen K; Kuller L; Panicali DL; Clements JD; Agy M; Montefiori DC; Hu SL; Bosch ML Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV89.6 | 0 | 0 |
| 78 | 1 | 13 | 57 2003 APR 11 AIDS 17(6):937-938
Youle M; Wainberg MA Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? | 0 | 0 |
| 79 | 1 | 91 | 92 2003 APR [15] JOURNAL OF VIROLOGY 77(8):4911-4927
Wherry EJ; Blattman JN; Murali-Krishna K; van der Most R; Ahmed R Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment | 0 | 14 |
| 80 | 2 | 81 | 118 2003 APR [15] TRENDS IN MOLECULAR MEDICINE 9(4):139-146
Vukmanovic S; Neubert TA; Santori FR Could TCR antagonism explain associations between MHC genes and disease? | 0 | 1 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 81 | 1 | 56 | 129 2003 MAY 10 VIROLOGY 309(2):272-281
Bu ZG; Ye L; Compans RW; Yang CL Enhanced cellular immune response against SIV Gag induced by immunization with DNA vaccines expressing assembly and release-defective SIV Gag proteins | 0 | 0 |
| 82 | 1 | 113 | 56 2003 MAY [15] ACTA TROPICA 86(2-3):315-333
Fincham JE; Markus MB; Adams VJ Could control of soil-transmitted helminthic infection influence the HIV/AIDS pandemic | 0 | 2 |
| 83 | 1 | 42 | 60 2003 MAY [15] AIDS RESEARCH AND HUMAN RETROVIRUSES 19(5):409-420
Bu ZG; Ye L; Skeen MJ; Ziegler HK; Compans RW; Yang CL Enhancement of immune responses to an HIV env DNA vaccine by a C-terminal segment of listeriolysin O | 0 | 1 |
| 84 | 2 | 31 | 65 2003 MAY-JUN [MAY 15] CLINICAL MEDICINE 3(3):269-272
McMichael A Prospects for an AIDS vaccine | 0 | 1 |
| 85 | 3 | 206 | 68 2003 MAY [15] CURRENT MOLECULAR MEDICINE 3(3):285-301
Ahlers JD; Belyakov IM; Berzofsky JA Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines | 0 | 4 |
| 86 | 1 | 77 | 75 2003 MAY [15] INTERNATIONAL JOURNAL FOR PARASITOLOGY 33(5-6):507-516
McVey DS; Galvin JE; Olson SC A review of the effectiveness of vaccine potency control testing | 0 | 0 |
| 87 | 3 | 101 | 120 2003 JUN 1 VACCINE 21():S68-S76
Lehner T Innate and adaptive mucosal immunity in protection against HIV infection | 0 | 2 |
| 88 | 2 | 57 | 93 2003 JUN [15] JOURNAL OF VIROLOGY 77(11):6197-6207
Megede JZ; Otten GR; Doe B; Liu H; Leung L; Ulmer JB; Donnelly JJ; Barnett SW Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA Vaccines | 0 | 0 |
| 89 | 2 | 40 | 94 2003 JUN [15] JOURNAL OF VIROLOGY 77(12):6743-6752
Karlsson AC; Deeks SG; Barbour JD; Heiken BD; Younger SR; Hoh R; Lane M; Sallberg M; Ortiz GM; Demarest JF; Liegler T; Grant RM; Martin JN; Nixon DF Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene | 0 | 1 |
| 90 | 1 | 53 | 95 2003 JUN [15] JOURNAL OF VIROLOGY 77(12):6889-6898
Migueles SA; Laborico AC; Imamichi H; Shupert WL; Royce C; McLaughlin M; Ehler L; Metcalf J; Liu SY; Hallahan CW; Connors M The differential ability of HLA b*5701(+) long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences | 2 | 4 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 91 | 3 | 34 | 125 2003 [JUN 30] VIRAL IMMUNOLOGY 16(2):203-212
Gaur A; Green WR Analysis of the helper virus in murine retrovirus-induced immunodeficiency syndrome: Evidence for immunoselection of the dominant and subdominant CTL epitopes of the BM5 ecotropic virus | 0 | 0 |
| 92 | 2 | 52 | 81 2003 JUL 1 JOURNAL OF IMMUNOLOGY 171(1):307-316
Lopes AR; Jaye A; Dorrell L; Sabally S; Alabi A; Jones NA; Flower DR; De Groot A; Newton P; Lascar RM; Williams I; Whittle H; Bertoletti A; Borrow P; Maini MK Greater CD8(+) TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection | 0 | 1 |
| 93 | 1 | 75 | 70 2003 JUL 15 FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 37(2-3):129-134
Fouts TR; DeVico AL; Onyabe DY; Shata MT; Bagley KC; Lewis GK; Hone DM Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1 | 0 | 1 |
| 94 | 1 | 88 | 86 2003 JUL 15 JOURNAL OF INFECTIOUS DISEASES 188(2):179-193
Gilbert PB; DeGruttola VG; Hudgens MG; Self SG; Hammer SM; Corey L What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: Issues involving surrogate end points in phase 3 trials | 0 | 1 |
| 95 | 1 | 51 | 96 2003 JUL [15] JOURNAL OF VIROLOGY 77(13):7319-7329
Venter M; Rock M; Puren AJ; Tiemessen CT; Crowe JE Respiratory syncytial virus nucleoprotein-specific cytotoxic T-cell epitopes in a South African population of diverse HLA types are conserved in circulating field strains | 0 | 1 |
| 96 | 6 | 51 | 97 2003 JUL [15] JOURNAL OF VIROLOGY 77(13):7330-7340
Altfeld M; Addo MM; Shankarappa R; Lee PK; Allen TM; Yu XG; Rathod A; Harlow J; O'Sullivan K; Johnston MN; Goulder PJR; Mullins JI; Rosenberg ES; Brander C; Korber B; Walker BD Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences | 2 | 7 |
| 97 | 3 | 31 | 98 2003 JUL [15] JOURNAL OF VIROLOGY 77(13):7367-7375
Barouch DH; Kunstman J; Glowczwskie J; Kunstman KJ; Egan MA; Peyerl FW; Santra S; Kuroda MJ; Schmitz JE; Beaudry K; Krivulka GR; Lifton MA; Gorgone DA; Wolinsky SM; Letvin NL Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys | 6 | 7 |
| 98 | 2 | 44 | 99 2003 JUL [15] JOURNAL OF VIROLOGY 77(13):7492-7501
Feeney ME; Roosevelt KA; Tang Y; Pfafferott KJ; McIntosh K; Burchett SK; Mao C; Walker BD; Goulder PJR Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children | 0 | 2 |
| 99 | 5 | 106 | 114 2003 JUL [15] NATURE MEDICINE 9(7):861-866
Letvin NL; Walker BD Immunopathogenesis and immunotherapy in AIDS virus infections | 1 | 11 |
| 100 | 2 | 15 | 122 2003 JUL 28 VACCINE 21(24):3370-3373
Ruprecht RM; Ferrantelli F; Kitabwalla M; Xu WD; McClure HM Antibody protection: passive immunization dof neonates against oral AIDS virus challenge | 1 | 2 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 101 | 3 | 74 | 76 2003 AUG 1 JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 33(4):426-438
Sabbaj S; Bansal A; Ritter GD; Perkins C; Edwards BH; Gough E; Tang JM; Szinger JJ; Korber B; Wilson CM; Kaslow RA; Mulligan MJ; Goepfert PA Cross-reactive CD8(+) T cell epitopes identified in US adolescent minorities | 0 | 1 |
| 102 | 1 | 44 | 87 2003 AUG [15] JOURNAL OF MEDICAL PRIMATOLOGY 32(4-5):180-186
Gardner MB Simian AIDS: an historical perspective | 0 | 0 |
| 103 | 2 | 66 | 100 2003 AUG [15] JOURNAL OF VIROLOGY 77(16):8607-8620
Patterson LJ; Malkevitch N; Pinczewski J; Venzon D; Lou YM; Peng B; Munch C; Leonard M; Richardson E; Aldrich K; Kalyanaraman VS; Pavlakis GN; Robert-Guroff M Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120 | 0 | 2 |
| 104 | 3 | 70 | 101 2003 AUG [15] JOURNAL OF VIROLOGY 77(16):9029-9040
O'Connor DH; Mothe BR; Weinfurter JT; Fuenger S; Rehrauer WM; Jing PC; Rudersdorf RR; Liebl ME; Krebs K; Vasquez J; Dodds E; Loffredo J; Martin S; McDermott AB; Allen TM; Wang CX; Doxiadis GG; Montefiori DC; Hughes A; Burton DR; Allison DB; Wolinsky SM; Bontrop R; Picker LJ; Watkins DI Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses | 0 | 3 |
| 105 | 1 | 57 | 123 2003 SEP 8 VACCINE 21(25-26):4022-4035
Zhao J; Lou YM; Pinczewski J; Malkevitch N; Aldrich K; Kalyanaraman VS; Venzon D; Peng B; Patterson LJ; Edghill-Smith Y; Woodward R; Pavlakis GN; Robert-Guroff M Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants | 0 | 2 |
| 106 | 1 | 28 | 64 2003 SEP [15] BIOMETRICS 59(3):531-541
Gilbert PB; Bosch RJ; Hudgens MG Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials | 0 | 2 |
| 107 | 2 | 24 | 102 2003 SEP [15] JOURNAL OF VIROLOGY 77(18):10113-10118
Subbramanian RA; Kuroda MJ; Charini WA; Barouch DH; Costantino C; Santra S; Schmitz JE; Martin KL; Lifton MA; Gorgone DA; Shiver JW; Letvin NL Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys | 0 | 0 |
| 108 | 1 | 48 | 130 2003 SEP 15 VIROLOGY 314(1):134-146
Muthumani K; Zhang DH; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo | 0 | 0 |
| 109 | 1 | 5 | 110 2003 SEP 20 LANCET 362(9388):993-994
Fitzgerald DW; Pape JW; Wasserheit JN; Counts GW; Corey L Provision of treatment in HIV-1 vaccine trials in developing countries | 0 | 0 |
| 110 | 2 | 38 | 77 2003 OCT 1 JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 34(2):214-220
van Ballegooijen M; Bogaards JA; Weverling GJ; Boerlijst MC; Goudsmit J AIDS vaccines that allow HIV-1 to infect and escape immunologic control - A mathematic analysis of mass vaccination | 0 | 0 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 111 | 2 | 47 | 124 2003 OCT 1 VACCINE 21(27-30):4380-4389
van Harmelen JH; Shephard E; Thomas R; Hanke T; Williamson AL; Williamson C Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa | 0 | 0 |
| 112 | 1 | 37 | 61 2003 OCT [15] AIDS RESEARCH AND HUMAN RETROVIRUSES 19(10):891-900
Buge SL; Ma HL; Amara RR; Wyatt LS; Earl PL; Villinger F; Montefiori DC; Staprans SI; Xu Y; Carter E; O'Neil SP; Herndon JG; Hill E; Moss B; Robinson HL; McNicholl JM Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: Poorer control of a pathogenic viral challenge | 0 | 0 |
| 113 | 1 | 55 | 66 2003 OCT [15] COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES 26(5-6):357-372
Puaux AL; Michel ML New gene-based approaches for an AIDS vaccine | 0 | 0 |
| 114 | 1 | 59 | 74 2003 OCT [15] INTERNATIONAL IMMUNOLOGY 15(10):1161-1171
Haicheur N; Benchetrit F; Amessou M; Leclerc C; Falguieres T; Fayolle C; Bismuth E; Fridman WH; Johannes L; Tartour E The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a T(h)1-dominant polarization | 0 | 0 |
| 115 | 1 | 33 | 103 2003 OCT [15] JOURNAL OF VIROLOGY 77(19):10348-10356
Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies | 1 | 3 |
| 116 | 2 | 52 | 104 2003 OCT [15] JOURNAL OF VIROLOGY 77(20):10829-10840
Igarashi T; Endo Y; Nishimura Y; Buckler C; Sadjadpour R; Donau OK; Dumaurier MJ; Plishka RJ; Buckler-White A; Martin MA Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes | 0 | 1 |
| 117 | 2 | 57 | 105 2003 OCT [15] JOURNAL OF VIROLOGY 77(20):10889-10899
McGettigan JP; Naper K; Orenstein J; Koser M; McKenna PM; Schnell MJ Functional human immunodeficiency virus type 1 (HIV-1) gag-pol or HIV-1 Gag-Pol and Env expressed from a single rhabdovirus-based vaccine vector genome | 0 | 0 |
| 118 | 1 | 27 | 58 2003 OCT 17 AIDS 17(15):2149-2157
Currier JR; Dowling WE; Wasunna KM; Alam U; Masons CJ; Robb ML; Carr JK; McCutchan FE; Birx DL; Cox JH Detection of high frequencies of HIV-1 cross-subtype reactive CD8 T lymphocytes in the peripheral blood of HIV-1-infected Kenyans | 0 | 0 |
| 119 | 1 | 34 | 73 2003 OCT 31 IMMUNOLOGY LETTERS 89(2-3):207-214
Majumder B; Gray B; McBurney S; Schaefer TM; Dentchev T; Mahalingam S; Reinhart TA; Ayyavoo V Attenuated nef DNA vaccine construct induces cellular immune response: role in HIV-1 multiprotein vaccine | 0 | 0 |
| 120 | 3 | 56 | 79 2003 NOV 7 JOURNAL OF BIOLOGICAL CHEMISTRY 278(45):44816-44825
Smith SM; Pentlicky S; Klase Z; Singh M; Neuveut C; Lu CY; Reitz MS; Yarchoan R; Marx PA; Jeang KT An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection | 0 | 0 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 121 | 4 | 93 | 82 2003 NOV 15 JOURNAL OF IMMUNOLOGY 171(10):5611-5623
Wilson CC; McKinney D; Anders M; MaWhinney S; Forster J; Crimi C; Southwood S; Sette A; Chesnut R; Newman MJ; Livingston BD Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1 | 0 | 0 |
| 122 | 6 | 73 | 106 2003 NOV [15] JOURNAL OF VIROLOGY 77(21):11563-11577
Doria-Rose NA; Ohlen C; Polacino P; Pierce CC; Hensel MT; Kuller L; Mulvania T; Anderson D; Greenberg PD; Hu SL; Haigwood NL Multigene DNA priming-boosting vaccines protect macaques from acute CD4(+)-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge | 1 | 1 |
| 123 | 3 | 51 | 119 2003 NOV [15] TRENDS IN MOLECULAR MEDICINE 9(11):468-473
Pantophlet R; Burton DR Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies | 0 | 0 |
| 124 | 2 | 38 | 83 2003 DEC 1 JOURNAL OF IMMUNOLOGY 171(11):6032-6038
Jiang J; Zenewicz LA; San Mateo LR; Lau LL; Shen H Activation of antigen-specific CD8 T cells results in minimal killing of bystander bacteria | 0 | 0 |
| 125 | 5 | 59 | 116 2003 DEC 9 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 100(25):15131-15136
Nishimura Y; Igarashi T; Haigwood NL; Sadjadpour R; Donau OK; Buckler C; Plishka RJ; Buckler-White A; Martin MA Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development | 0 | 1 |
| 126 | 2 | 31 | 84 2003 DEC 15 JOURNAL OF IMMUNOLOGY 171(12):6774-6779
Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HCJ Induction of CD8(+) T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers | 0 | 1 |
| 127 | 3 | 47 | 85 2003 DEC 15 JOURNAL OF IMMUNOLOGY 171(12):6875-6882
Brown K; Gao WT; Alber S; Trichel A; Murphey-Corb M; Watkins SC; Gambotto A; Barratt-Boyes SM Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys | 0 | 1 |
| 128 | 4 | 53 | 107 2003 DEC [15] JOURNAL OF VIROLOGY 77(23):12430-12440
Geels MJ; Cornelissen M; Schuitemaker H; Anderson K; Kwa D; Maas J; Dekker JT; Baan E; Zorgdrager F; van den Burg R; van Beelen M; Lukashov VV; Fu TM; Paxton WA; van der Hoek L; Dubey SA; Shiver JW; Goudsmit J Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual | 0 | 1 |
| 129 | 3 | 37 | 108 2003 DEC [15] JOURNAL OF VIROLOGY 77(23):12572-12578
Peyerl FW; Barouch DH; Yeh WW; Bazick HS; Kunstman J; Kunstman KJ; Wolinsky SM; Letvin NL Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope | 1 | 1 |
| 130 | 2 | 41 | 109 2003 DEC [15] JOURNAL OF VIROLOGY 77(23):12764-12772
Kong WP; Huang Y; Yang ZY; Chakrabarti BK; Moodie Z; Nabel GJ Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA Vaccines | 0 | 1 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 131 | 2 | 25 | 147 2004 JAN 1 JOURNAL OF INFECTIOUS DISEASES 189(1):71-74
Ferrantelli F; Kitabwalla M; Rasmussen RA; Cao C; Chou TC; Katinger H; Stiegler G; Cavacini LA; Bai Y; Cotropia J; Ugen KE; Ruprecht RM Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies - Implications for acquired immunodeficiency syndrome vaccine | 0 | 1 |
| 132 | 2 | 50 | 132 2004 JAN 2 AIDS 18(1):25-36
Bogers WMJM; Bergmeier LA; Ma J; Oostermeijer H; Wang YF; Kelly CG; ten Haaft P; Singh M; Heeney JL; Lehner T A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection | 0 | 0 |
| 133 | 1 | 43 | 159 2004 JAN 6 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 101(1):290-295
Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJH; Hill AVS A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses | 1 | 1 |
| 134 | 3 | 114 | 136 2004 JAN [15] CURRENT DRUG TARGETS 5(1):71-88
Stratov I; DeRose R; Purcell DFJ; Kent SJ Vaccines and vaccine strategies against HIV | 0 | 0 |
| 135 | 2 | 58 | 137 2004 JAN [15] DNA AND CELL BIOLOGY 23(1):1-13
Richardson MW; Sverstiuk AE; Silvera P; Greenhouse J; Lisziewicz J; Lori F; Khalili K; Lewis MG; Rappaport J T-cell receptor excision circles (TREC) in SHIV 89.6p and SlVmac251 models of HIV-1 infection | 0 | 0 |
| 136 | 4 | 90 | 148 2004 JAN [15] JOURNAL OF VIROLOGY 78(1):94-103
Tsui R; Herring BL; Barbour JD; Grant RM; Bacchetti P; Kral A; Edlin BR; Delwart EL Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure | 0 | 0 |
| 137 | 2 | 105 | 158 2004 JAN [15] NATURE REVIEWS GENETICS 5(1):52-61
Rambaut A; Posada D; Crandall KA; Holmes EC The causes and consequences of HIV evolution | 0 | 0 |
| 138 | 1 | 54 | 164 2004 FEB 5 VIROLOGY 319(1):118-130
Ellenberger D; Li B; Smith J; Yi H; Folks T; Robinson H; Butera S Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms | 0 | 0 |
| 139 | 2 | 37 | 142 2004 FEB [15] IMMUNOLOGY AND CELL BIOLOGY 82(1):55-61
Chao DL; Davenport MP; Forrest S; Perelson AS Modelling the impact of antigen kinetics on T-cell activation and response | 0 | 0 |
| 140 | 2 | 34 | 149 2004 FEB [15] JOURNAL OF VIROLOGY 78(3):1324-1332
Yokomaku Y; Miura H; Tomiyama H; Kawana-Tachikawa A; Takiguchi M; Kojima A; Nagai Y; Iwamoto A; Matsuda Z; Ariyoshi K Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection | 0 | 0 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 141 | 2 | 52 | 165 2004 MAR 1 VIROLOGY 320(1):167-180
Buckner C; Gines LG; Saunders CJ; Vojtech L; Srivastava I; Gettie A; Bohm R; Blanchard J; Barnett SW; Safrit JT; Stamatatos L Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV | 0 | 0 |
| 142 | 5 | 99 | 138 2004 MAR [15] EXPERT OPINION ON BIOLOGICAL THERAPY 4(3):349-361
Sommerfelt MA; Nyhus J; Sorensen B Novel peptide-based HIV-1 immunotherapy | 0 | 0 |
| 143 | 2 | 19 | 155 2004 MAR [15] NATURE MEDICINE 10(3):221-223
Desrosiers RC Prospects for an AIDS vaccine | 0 | 0 |
| 144 | 4 | 38 | 156 2004 MAR [15] NATURE MEDICINE 10(3):275-281
Friedrich TC; Dodds EJ; Yant LJ; Vojnov L; Rudersdorf R; Cullen C; Evans DT; Desrosiers RC; Mothe BR; Sidney J; Sette A; Kunstman K; Wolinsky S; Piatak M; Lifson J; Hughes AL; Wilson N; O'Connor DH; Watkins DI Reversion of CTL escape-variant immunodeficiency viruses in vivo | 0 | 1 |
| 145 | 8 | 45 | 157 2004 MAR [15] NATURE MEDICINE 10(3):282-289
Leslie AJ; Pfafferott KJ; Chetty P; Draenert R; Addo MM; Feeney M; Tang Y; Holmes EC; Allen T; Prado JG; Altfeld M; Brander C; Dixon C; Ramduth D; Jeena P; Thomas SA; St John A; Roach TA; Kupfer B; Luzzi G; Edwards A; Taylor G; Lyall H; Tudor-Williams G; Novelli V; Martinez-Picado J; Kiepiela P; Walker BD; Goulder PJR HIV evolution: CTL escape mutation and reversion after transmission | 1 | 2 |
| 146 | 3 | 46 | 160 2004 MAR [15] TRENDS IN IMMUNOLOGY 25(3):138-142
Yang OO CTL ontogeny and viral escape: implications for HIV-1 vaccine design | 0 | 0 |
| 147 | 1 | 42 | 154 2004 MAR 25 MACROMOLECULAR CHEMISTRY AND PHYSICS 205(5):684-691
Baigude H; Katsuraya K; Okuyama K; Uryu T Synthesis of structurally-controlled AIDS vaccine model with glyco-peptide dendrimer scaffolds | 0 | 0 |
| 148 | 1 | 64 | 133 2004 MAR 26 AIDS 18(5):709-718
Smith DE; Walker BD; Cooper DA; Rosenberg ES; Kaldor JA Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? | 0 | 0 |
| 149 | 1 | 9 | 134 2004 MAR 26 AIDS 18(5):817-819
Aleman S; Leitner T; Liu MA; Wahren B Minor nef gene alterations after human HIV-DNA immunisation | 0 | 0 |
| 150 | 6 | 63 | 143 2004 APR 5 JOURNAL OF EXPERIMENTAL MEDICINE 199(7):905-915
Draenert R; Le Gall S; Pfafferott KJ; Leslie AJ; Chetty P; Brander C; Holmes EC; Chang SC; Feeney ME; Addo MM; Ruiz LD; Ramduth D; Jeena P; Altfeld M; Thomas S; Tang TH; Verrill CL; Dixon C; Prado JG; Kiepiela P; Martinez-Picado J; Walker BD; Goulder PJR Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection | 0 | 1 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 151 | 7 | 219 | 135 2004 APR [15] CLINICAL MICROBIOLOGY REVIEWS 17(2):370-+
Giri M; Ugen KE; Weiner DB DNA vaccines against human immunodeficiency virus type 1 in the past decade | 0 | 0 |
| 152 | 3 | 70 | 150 2004 APR [15] JOURNAL OF VIROLOGY 78(7):3333-3342
Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WMJM; ten Haaft PJF; Niphuis H; Koornstra W; Bieler K; Kostler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection | 0 | 0 |
| 153 | 2 | 29 | 151 2004 APR [15] JOURNAL OF VIROLOGY 78(8):3930-3940
Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK Highly effective control of an AIDS virus challenge in macaques by using vesicular stornatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol | 0 | 0 |
| 154 | 2 | 34 | 161 2004 APR 16 VACCINE 22(13-14):1764-1772
Liu FJ; Mboudjeka I; Shen SY; Chou THW; Wang SX; Ross TM; Lu S Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model | 1 | 1 |
| 155 | 3 | 48 | 162 2004 APR 16 VACCINE 22(13-14):1773-1781
Toapanta FR; Ross TM Mouse strain-dependent differences in enhancement of immune responses by C3d | 0 | 0 |
| 156 | 3 | 52 | 163 2004 APR 16 VACCINE 22(13-14):1810-1819
Isaguliants MG; Zuber B; Boberg A; Sjostrand D; Belikov SV; Rollman E; Zuber AK; Rechinsky VO; Rytting AS; Kallander CFR; Hinkula J; Kochetkov SN; Liu M; Wahren R Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model | 0 | 0 |
| 157 | 2 | 62 | 131 2004 APR 19 ADVANCED DRUG DELIVERY REVIEWS 56(6):835-852
Crotty S; Andino R Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine | 0 | 0 |
| 158 | 7 | 44 | 144 2004 APR 19 JOURNAL OF EXPERIMENTAL MEDICINE 199(8):1053-1063
Cardinaud S; Moris A; Fevrier M; Rohrlich PS; Weiss L; Langlade-Demoyen P; Lemonnier FA; Schwartz O; Habel A Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames | 0 | 0 |
| 159 | 4 | 44 | 145 2004 MAY [15] JOURNAL OF GENERAL VIROLOGY 85():1191-1201
Negri DRM; Baroncelli S; Catone S; Comini A; Michelini Z; Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Mancini MG; Farcomeni S; Fagrouch Z; Ciccozzi M; Boros S; Lijestrom P; Norley S; Heeney J; Titti F Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge | 0 | 0 |
| 160 | 1 | 46 | 146 2004 MAY 15 JOURNAL OF IMMUNOLOGY 172(10):6152-6157
de Groot N; Doxiadis GG; de Groot NG; Otting N; Heijmans C; Rouweler AJM; Bontrop RE Genetic makeup of the DR region in rhesus macaques: Gene content, transcripts, and pseudogenes | 0 | 0 |
| # | LCR | NCR | Nodes / Authors / Date | LCS | GCS |
| 161 | 3 | 70 | 152 2004 MAY [15] JOURNAL OF VIROLOGY 78(9):4463-4477
Kaufmann DE; Bailey PM; Sidney J; Wagner B; Norris PJ; Johnston MN; Cosimi LA; Addo MM; Lichterfeld M; Altfeld M; Frahm N; Brander C; Sette A; Walker BD; Rosenberg ES Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides | 0 | 0 |
| 162 | 6 | 105 | 153 2004 MAY [15] JOURNAL OF VIROLOGY 78(10):5324-5337
Van Rompay KKA; Singh RP; Pahar B; Sodora DL; Wingfield C; Lawson JR; Marthas ML; Bischofberger N CD8(+)-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment | 0 | 0 |
| 163 | 2 | 106 | 139 2004 JUN [15] IMMUNOLOGICAL REVIEWS 199(1):84-99
Calarota SA; Weiner DB Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants | 0 | 0 |
| 164 | 2 | 104 | 140 2004 JUN [15] IMMUNOLOGICAL REVIEWS 199(1):126-143
Moore AC; Hill AVS Progress in DNA-based heterologous prime-boost immunization strategies for malaria | 0 | 0 |
| 165 | 5 | 128 | 141 2004 JUN [15] IMMUNOLOGICAL REVIEWS 199(1):144-155
Estcourt MJ; McMichael AJ; Hanke T DNA vaccines against human immunodeficiency virus type 1 | 0 | 0 |
Generated by: HistCite(Vlad).
Version: 2004.05.14